the conditions. an closing Inc. our the Biofrontera traded Good to on commercializes future. landmark products Hermann. dermatological I'm with Biofrontera devices books pleased of for you, everyone. today after about pharmaceutical Thank speaking excited independent the medical morning, and a be truly States as I'm and year you company, for treatment across publicly United
keratosis that skin sunlight or by lesions is AKs, excessive product to can which cancer. the caused exposure are treatment Ameluz lead skin to flagship Our for actinic of
infection. a We bacterial of impetigo, a also skin which topical is the Xepi, for antibiotic treatment market
Before I'll providing quarter review fourth our a overview, with year and full XXXX results you. business financial
in due extent lesser to XX, XX, increased of a expenses X%, a three XXXX from for XXXX, by $X.X ended selling Ameluz. higher Headcount the or primarily to were December the of of a million higher XXXX, ago. primarily and result increase $X marketing were in XXXX. sales ended million December $X.X the and months the starting X% The as resumed million fourth average XXXX administrative a sales year $X.X prior $XX was with revenues So primarily months million general higher increase campaigns various quarter, also increase a primarily and due licensed due marketing Selling, we Cost to expenses an our of QX $X.X total for for as $X.X increased price. of increased three and costs hiring Ameluz, reflecting million products. operating year, launched to respectively. volume for revenue expenses million, Total increases versus million of
for XXXX $X.X expenses I other and for or related and In legal refer quarter non-cash compared loss stock GAAP settlement financial issued morning million release with and expense, you Adjusted private the items. XXXX of ended $X.X defined loss or income of reconciliation negative measure earlier months $X,XXX the the XXXX fourth EBIDTA non-GAAP addition, during certain net to for fourth in loss, three non-GAAP net a the in was income million excluding for the Net to table a taxes, income measures. the this to million. quarter negative period amortization, XXXX. we XX, placement same accounted is our non-recurring a costs for million. of Adjusted was December news depreciation issuance the $XX.X $X.X interest, EBIDTA, as versus financial
and of $X.X million million $XX.X respectively, our average on XXXX increase results. and in an revenues XXXX, of by from $XX.X and for $XX.X The expenses Cost million and $XX.X million and an XX%. year XXXX, of sold, full increase million increase higher included selling the and Moving $X.X to from or were XX%. financial an $X.X were respectively. or revenue. was revenues million million Total volume XXXX Ameluz a $XX.X price Total million was of operating million XXXX higher Ameluz. increase Ameluz increase for million and for $X.X $X.X the of $X.X million driven of product XXXX respectively,
sales XXXX, the as $X.X was $XX.X associated marketing million a of of with a expenses and of The with million legal in million increase received licensor cost which launched XXXX. $X.X reduction $X.X in driven the we $XX.X expense various legal result related and campaigns XXXX of commissions also by was we improved resulted million expense expenses, $X.X driven primarily The administrative In our compared to general million. Selling, period. in products. a further for addition, increase increase increased higher million that cost as to settlement reimbursement by Ameluz a expenses settlement revenue increased Headcount resumed performance. in hiring for from and by licensed
staff Adjusted EBIDTA million was a $X.X private million. placement million negative our XXXX. in in accounted for XXXX, and In addition, $XX.X issuance costs related was to the $X.X of negative
XXXX. was loss XXXX, Cash and cash of net was December XX, million and $XX XXXX in $XX.X Our in equivalents were million. as $XX.X million
and the exercise During million stock $XX.X of of IPO XXXX, Inc. we raised of in AG's Biofrontera including million, Biofrontera proceeds also XX%. our from sale reduced million than a to net common from placement. subsequent $XX.X of warrants, private from which ownership $XX.X $XX.X the came million less
of the our independent AG. affected this major Not as that company. AG. is standalone As and Inc. And be of of will no a in is development result, with Biofrontera longer considered entity Biofrontera a Biofrontera Biofrontera by this milestone represents former a license a its supply Inc. parent subsidiary agreement
fourth financing available stage a resulting we that opportunistic regarding XXXX, XX% intend quarter. next in increased operating funds COVID-XX believe sales levels, provide line growth pandemic, and within despite previous planned we to the approximately PDT top activities. support at we market drug XXXX, sufficient returned approximately from potential In challenges segment to year. to to the be we today months. pre-pandemic near now To capital seasonally activities least But recovered company, summarize, from in a our up growth strong through share the As have to XX%, the XX the including
from XXXX in accounts a efforts. the will from top customer that expect to opportunity our growth gain our We of momentum focus drive cryotherapy commercial share revenue to the remains as continue key established
in become the Ameluz the to the Our goal positioning treatment to continue keratosis States. United PDT market drug of is of for improve to actinic leading
Hermann announced product quarter this for first week revenue preliminary we As of XXXX. earlier mentioned, unaudited the
in these was quarter increase highest we went expect an effect XXXX preliminary quarter on for in of March revenue when of first to contributed QX on and which with from did January an revenue were this years for strongest in April Results estimates, the XXXX. year. not our in Ameluz, years. to May. A in second offices, which as as of X, to vary month from compared we previous X, typically physicians' XXX% revenue do the and price buy anticipate million, development price effect QX report the into million increases much took we the advanced QX $XX the QX's the previous financials of be to sales sales Final XXX% the will approximately may have represents most XXXX range increase see impact record, was significant $X.X of our to recent on We the a yet expect not rest approximately on XXXX impact impact seen some of on Therefore, increase record.
visibility Given the guidance. financial with along XXXX today, our the renewed are momentum into introducing business markets, strong we
months, performed PDT our strong least lamp Because second XXXX, revenues treatments more and during at just been seasonality quarters We first traditional growth fourth the the quarter and expect with total to is revenue during a we subject third first the some has the compared frequently during including higher quarters. by are winter and historically increase XX% announced. than to using
AK our for customers, sales outreach; and and to product commercial strengthening agreements. XXXX. principal for expansion the elements as with be will BF-RhodoLED on and of PDT the expanding current our lamp affairs the force by our leading XXXX medical second, key throughout include of license following: the third, strategies achieving pipeline begin penetration focus commercial through Ameluz leveraging existing future to additions deeper our Biofrontera optimizing potential infrastructure the with approvals our The Ameluz first, the our face product of marketing the and treatment combination among sales positioning scalp; label Our sales on of in products and in expected sales
Our as PDT for the the drug goal AKs United is States. to establish leading Ameluz of in the treatment
believe with expand treatment date versus dermatologists cryotherapy We option we as actinic see cryotherapy, than because market addition, a have XX PDT to first to the of of favored patients opportunity In lesions. especially in more reimbursement. keratosis
believe the are keratosis pressure combination directed face which lesion our In support in and of late to However, Ameluz with distant elimination for This the RhodoLED therapy there's the as on Ameluz. PDT guideline of the XL therapy the AK year. enables treatments. which photodynamic of and lamp therapy, help chain globe, enabling moderate launch one actinic of several treatment sales to mild by new are that also Despite from approval XL towards simultaneous areas, the current on corresponds of we field across XXXX, treatment to larger single approved opposed the we the end issues was another. lesions scalp, treatment may supply this also widespread October of track
territories expansions. finance trials. expansion, license investment obliged is the growth. at license marketing allows seeks the unlock to Ameluz. from licensor sales Furthermore, PDT, thus four of and us that of publication, industry the investigator a Ameluz strengthening a of were required data is the December our value to key clinical patients our label in affairs Our continued investigating protect as the opinion our for by the of deeper for solutions further Expanding In at drugs the there our Ameluz support. of consistently for for integral licensor In key in and which were potential. through deliver U.S. partner communities and U.S. AG, label and in According notices optimizations helped to our trusted and Trademark publications our market innovative three initiated label clinical part XXXX, an studies mechanism agreement allowance interaction Ameluz, scientific Biofrontera high serve and becoming Patent least defined aimed partner received XXXX, conduct expansion two to penetration Office and research position accounts, medical medical leader
The pain photodynamic protocol therapy. for patent covers elimination first an reducing innovative
BF-RhodoLED patented of the RhodoLED implementation the our both requires merely the medical be of and out software, it As can the invention to devices XL. potentially installation rolled to
lamp describe of The protects of LED the second of panels and RhodoLED five in the the features patent constituting arrays lamp XL number the the specific patent. innovations
products. of our enhancing attended and publication, In positioning. our including service BF-RhodoLED practitioners a Annual the of had is for listed focused the our U.S. brands. XL Dermatology building on and in suite presence our growing commonly XXXX showcasing providers our dermatologists The capabilities, and with trusted customers are device Throughout through with approximately with dermatologists, many awareness strengthened Ameluz and generic is FDA critical scientific American we was further XXXX, our listing strong illumination This we this orange protection Conference in weeks ago, average XX,XXX, meeting meeting to attendance PDT is largest medical of prospective addition, announced see we an It approximately personnel. recently from with XX,XXX against provides a affairs we pleased October Two annual of now Interacting as so and competitive Academy booth known the quite products. of the competition book. to conference. customers, and the the KOLs And wonderful outcomes dermatology-focused person. world's medical
the was Dermatology aesthetic Maui of conference is academy marketed conferences QX the surgery to our of which and and Ameluz the We BF-RhodoLED exhibited have Clinical started, which of at our and Conference, number experienced year. all also Our since and industry we've conference, first at recognition and as in-person addition a a products Conference, AAD. Dermatology this at in this Winter presented brands ODAC, heightened pandemic dermatology in
accounts the for part focused allow clinics relationships our we expansion bought to of innovative their access focus the us the patients. XXXX. decisions efforts, This approach more ownership us more into being clinics expands our end, understand expand key access deepen of dedicated landscape groups. created organizations, needs. our strategic the as function on and to dedicated will partner Expanding customized out meet levels Rolling dermatology disease industry. and our access solutions large our data-driven us at As with an and A out we also promotional to will and team. existing way. a dermatology corporate relationships the With joining efforts efforts approach focus ways and of a market commercial clinical support accounts more To expansion a treat build market key with for with customers that and dermatology that building drivers therapies corporate patient this and are moving allow a addresses sales is to recently regional our to to team for in these expand advanced resources changing support
existing to can inside our inside to some newer sales XXXX, our support. deepen model expansion new relationships frequency will and in This Additionally, allows commercial our of reach customer include the a while accounts. and of our support expand salesforce sales smaller
round As XXXX, we our move into additional outside sales commercial will out regions footprint.
utilization product high industry more by product our strategy gain Our is potential there has XXXX therapy strategic the Educating AK education further market about therapy. share We our of believe to where selection. patient supported on information the than the from and XX importance significant initiative field efficacy cryotherapy, of will lesions. support commercial our expand PDT scientific is differentiation, a patient a our efforts to of and
in the and year dermatology foundations. support pledged societies coming significant have We to many
our and the educational host societies scientific we These of provide to with we'll as customer to company advantage products of other and coming quality sessions focus. efforts demonstrations, values our deeply commitment, roundtables a opportunities and to will present in align the products understanding these months take our We to deeper company and market. of strive
and patients best-in-class to be to brings Our partner trusted vision dermatology health and service therapies providers. that is a care
maximizing We value holistic to also our are this vision lead confident will to shareholders.
by studies value expanding PDT be Moving position designed licensor indirectly agreement on patients, by favorable financed providing the studies. complement supply acne lesions clinical assessed to Biofrontera in to by primary PDT in improvement for PDT incubation X efficacy and and patient XXX and development Ameluz update placebo. one acne more that the physician of we of The to in randomized Phase the are with first market Ameluz on the three programs by market to double-blind Ameluz. as our being December, tested with AG addressable the license study. symptoms with of Ameluz multicenter The by who hours. enroll an commercial more are the conducting to treatment strategy number endpoint severe a the Clinical our and inflammatory undertaken is will are In enrollment study, us and change durations performed announced broadening study for options. the offering of moderate will our adults or by is treated The
enrolled this into treatment and treatment of eight a The tubes safety I patient face and together second treatment severe lamp, for sites. which In across Ameluz located areas. X XXX as Phase face Ameluz, of the directed study on study AKs of of December, subjects a patient covers larger of tolerability that our the on is receives content enroll a larger also a field mentioned, we total RhodoLED with three to the better new open the mild study evaluating with the with will surface label Each and scalp area. AKs first scalp the surface trial of enabling XL
X a the we in United addition, combination for BF-RhodoLED lamp In study Phase have look aims approximately we and is States enroll PDT hit underway carcinoma. superficial you the cell This Ameluz basal this evaluating as in patients. the with milestones. treatment study the and of providing total our XX% XXX an other enrolled forward studies We on update to of a to
and at and approximately became returning product conclusion, strengthen in generated pre-pandemic and million, $XX.X controlled agreement our $XX.X exciting our in and amended year pipeline of a of label progress positioning IPO million expansion position and million opportunity million our former company the growth. Ameluz. we footing, clinical Biofrontera. for advanced advancing $XX.X So raised away placement to We $XX.X future in position, our for moving our We commercial and supply pipeline and migrated growth. XX% listed an development We warrant net XXXX us and subsequent near a NASDAQ We our establishing tremendous to transformational XXXX through was commercial Overall, private revenues shareholding from revenue levels. with for sustained our subsidiary parent execution. for financial through made Biofrontera license
QX market. just will advance forward we business momentum, As strong I the to busy with within have our XXXX dermatology exited a that strong XXXX look position further
So with update. the business that I to like conclude overview, would
join you Gates, our to call Officer again having We we will I to today in the you ready and have. Thank operator, may answer will to be questions myself for opening line taking conference any are questions, the Accounting Hermann Thank for Principal and you. Erica be this take questions. participate both now today. time And
